The relationship of antidepressant prescribing concentration to treatment duration and cost

Journal of Mental Health Policy and Economics

Volumn 15, Issue 1, 2012, Pages 3-11

  Hodgkin, Dominic ^a   Merrick, Elizabeth L ^a   Hiatt, Deirdre ^b  

^a BRANDEIS UNIVERSITY   (United States)

^b Health Net   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; DEPRESSION; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PRESCRIPTION; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; COST SAVINGS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; DRUGS, GENERIC; FEMALE; FINANCING, PERSONAL; HEALTH EXPENDITURES; HUMANS; INDIVIDUALIZED MEDICINE; INSURANCE, PHARMACEUTICAL SERVICES; LONG-TERM CARE; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES; YOUNG ADULT;

EID: 84862505275     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. National Advisory Mental Health Council. From Discovery to Cure: Accelerating the Development of New and Personalized Interventions for Mental Illnesses.; 2010.
2. National Institute of Mental Health. NIMH Strategic Plan; 2008.
3. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M; STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-1242.
4. Basu A. Individualization at the heart of comparative effectiveness research: the time for i-CER has come. Med Decis Making 2009;29:NP9-NP11.
5. Frank RG, Zeckhauser RJ. Custom-made versus ready-to-wear treatments: behavioral propensities in physicians' choices. J Health Econ 2007;26:1101-1127. (Pubitemid 350166636)
6. Taub A, Kolotilin A, Gibbons RS, Berndt ER. The Diversity of Concentrated Prescribing Behavior: An Application to Antipsychotics In: NBER Working Paper; 2011.
7. Stern S, Trajtenberg M. Empirical Implications of Physician Authority in Pharmaceutical Decisionmaking. In: NBER Working Paper 1998.
8. Merrick E, Hodgkin D, Panas L, Soumerai SB, Ritter G. Is customization in antidepressant prescribing associated with acute-phase treatment adherence? Journal of Pharmaceutical Health Services Research 2011;In press.
9. Joyce GF, Carrera MP, Goldman DP, Sood N. Physician prescribing behavior and its impact on patient-level outcomes. Am J Manag Care 2011;17:e462-71.
10. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653-661. (Pubitemid 36246547)
11. American Psychiatric Association. Treatment of patients with major depressive disorder; 2010.
12. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002;105:164-172. (Pubitemid 34280688)
13. Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W, Mesters P. Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry 2001;62 Suppl 22:30-33. (Pubitemid 32937583)
14. Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, Fireman B. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002;288:1403-1409. (Pubitemid 35025915)
15. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-457. (Pubitemid 41022729)
16. Bryson CL, Au DH, Young B, McDonell MB, Fihn SD. A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp). Med Care 2007;45:497-504.
17. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40:1280-1288. (Pubitemid 44204957)
18. Kwon A, Bungay KM, Pei Y, Rogers WH, Wilson IB, Zhou Q, Adler DA. Antidepressant use: concordance between self-report and claims records. Med Care 2003;41:368-374.
19. Scherer FM, Ross DR. Industrial Market Structure and Economic Performance. 2nd ed: Houghton Mifflin Harcourt; 1980.
20. Kaiser U, Mendez, Susan J, Rønde, Thomas Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark: Center for European Economic Research; 2010.
21. Leslie DL, Rosenheck RA. Diversity versus concentration in antipsychotic drug selection. J Ment Health Policy Econ 2008;11:107-112.
22. Greene W. Econometric Analysis. Prentice-Hall.; 1993.
23. Hodgkin D, Horgan CM, Garnick DW, Len Merrick E, Volpe-Vartanian J. Management of access to branded psychotropic medications in private health plans. Clin Ther 2007;29:371-380. (Pubitemid 46654225)
24. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff 2004;23:135-146. (Pubitemid 39115293)
25. Huskamp HA. Pharmaceutical cost management and access to psychotropic drugs: the U.S. context. Int J Law Psychiatry 2005;28:484-95. (Pubitemid 41338401)
26. Keilman J. Illinois limits psychiatric drugs for Medicaid patients. Chicago Tribune 2011 September 7.
27. Simon G. Choosing a first-line antidepressant: equal on average does not mean equal for everyone. JAMA 2001;286:3003-3004. (Pubitemid 33140366)
28. Pomerantz JM, Finkelstein SN, Berndt ER, Poret AW, Walker LE, Alber RC, Kadiyam V, Das M, Boss DT, Ebert TH. Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis. J Clin Psychiatry 2004;65:395-404.